In today’s session Ophthotech Corp (OPHT) recorded an unusually high (431) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious OPHT decrease. With 431 contracts traded and 10584 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: OPHT170120P00035000 closed last at: $15 or 5.7% down. About 311,615 shares traded hands. Ophthotech Corp (NASDAQ:OPHT) has declined 35.99% since April 28, 2016 and is downtrending. It has underperformed by 41.91% the S&P500.
Analysts await Ophthotech Corp (NASDAQ:OPHT) to report earnings on February, 22. They expect $-1.46 earnings per share, down 43.14% or $0.44 from last year’s $-1.02 per share. After $-1.71 actual earnings per share reported by Ophthotech Corp for the previous quarter, Wall Street now forecasts -14.62% EPS growth.
Ophthotech Corp (NASDAQ:OPHT) Ratings Coverage
Out of 10 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 9 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 90% are positive. $200 is the highest target while $45 is the lowest. The $97.33 average target is 217.24% above today’s ($30.68) stock price. Ophthotech Corporation has been the topic of 14 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Citigroup given on Thursday, August 4. The firm has “Sell” rating given on Friday, August 7 by Goldman Sachs. Chardan Capital Markets maintained Ophthotech Corp (NASDAQ:OPHT) on Monday, December 14 with “Buy” rating. The company was maintained on Thursday, August 6 by Stifel Nicolaus. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Buy” rating given on Tuesday, September 8 by Chardan Capital Markets. The firm earned “Buy” rating on Thursday, January 7 by SunTrust. The rating was initiated by Suntrust Robinson with “Buy” on Friday, January 8. The rating was initiated by Barclays Capital with “Overweight” on Wednesday, April 27. On Friday, August 14 the stock rating was reinitiated by Oppenheimer with “Outperform”. The stock of Ophthotech Corp (NASDAQ:OPHT) has “Buy” rating given on Tuesday, August 4 by Chardan Capital Markets.
According to Zacks Investment Research, “Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 1.15 in 2016 Q2. Its down 0.80, from 1.95 in 2016Q1. The ratio fall, as 21 funds sold all Ophthotech Corp shares owned while 34 reduced positions. 38 funds bought stakes while 69 increased positions. They now own 41.31 million shares or 29.52% more from 31.90 million shares in 2016Q1.
Rhumbline Advisers has 0% invested in the company for 30,112 shares. Highland Capital Management Lp owns 13,710 shares or 0.03% of their US portfolio. Great West Life Assurance Can accumulated 0% or 2,200 shares. The Maryland-based Proshare Advsrs Llc has invested 0.02% in Ophthotech Corp (NASDAQ:OPHT). Ameriprise holds 30,192 shares or 0% of its portfolio. The Ontario – Canada-based Mackenzie Financial Corporation has invested 0.01% in Ophthotech Corp (NASDAQ:OPHT). Tudor Corp Et Al accumulated 0.01% or 10,501 shares. Moreover, Mutual Of America Capital Mgmt Ltd Liability Corporation has 0% invested in Ophthotech Corp (NASDAQ:OPHT) for 800 shares. Creative Planning, a Kansas-based fund reported 5,527 shares. Opaleye Management Inc last reported 8.20 million shares in the company. Goldman Sachs Grp Incorporated last reported 277,593 shares in the company. Baker Bros Ltd Partnership last reported 0.02% of its portfolio in the stock. Bancorp Of America De has invested 0% of its portfolio in Ophthotech Corp (NASDAQ:OPHT). Silvercrest Asset Management Group Limited Liability last reported 0.01% of its portfolio in the stock. Ghost Tree Ltd Limited Liability Company holds 215,000 shares or 3.17% of its portfolio.
Insider Transactions: Since June 3, 2016, the stock had 0 insider buys, and 9 selling transactions for $11.42 million net activity. $1.06M worth of Ophthotech Corp (NASDAQ:OPHT) was sold by PATEL SAMIR CHANDRAKANT. GUYER DAVID R also sold $1.25M worth of Ophthotech Corp (NASDAQ:OPHT) shares. Shares for $199,395 were bought by Bolte Axel on Friday, June 3.
Ophthotech Corporation is a biopharmaceutical company. The company has a market cap of $986.42 million. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration . It currently has negative earnings. The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
OPHT Company Profile
Ophthotech Corporation, incorporated on January 5, 2007, is a biopharmaceutical company. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV), a specific type of wet AMD. It is also investigating the potential of an ophthalmic formulation for tivozanib, a molecule VEGF tyrosine kinase inhibitor, for which the Company has an option for a license.
More important recent Ophthotech Corp (NASDAQ:OPHT) news were published by: Fool.com which released: “Here’s Why Ophthotech Corporation Is Dropping Today” on September 30, 2016, also Fool.com published article titled: “Why Ophthotech Corp. Shares Soared 14.9% in May”, Fool.com published: “Why Ophthotech Corp. Plunged 42% in March” on April 07, 2016. More interesting news about Ophthotech Corp (NASDAQ:OPHT) was released by: Reuters.com and their article: “BRIEF-Ophthotech Corp & Ajinomoto Althea entered into a clinical and comme…” with publication date: November 04, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.